# reload+after+2024-01-22 06:47:05.022382
address1§2100 East 54th Street North
city§Sioux Falls
state§SD
zip§57104
country§United States
phone§605 679 6980
website§https://www.sabbiotherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.
fullTimeEmployees§56
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Samuel J. Reich', 'age': 48, 'title': 'Executive Chairman', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 376200, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Eddie Joe Sullivan Ph.D.', 'age': 57, 'title': 'Co-Founder, President, CEO & Director', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 430617, 'exercisedValue': 0, 'unexercisedValue': 23217}, {'maxAge': 1, 'name': 'Ms. Christine E. Hamilton M.B.A.', 'age': 67, 'title': 'Co-Founder & Independent Director', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 25000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Alexandra  Kropotova M.B.A., M.D.', 'age': 50, 'title': 'Executive VP & Chief Medical Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 486957, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Edward D. Hamilton D.V.M.', 'title': 'Co-Founder & Board Observer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael George King Jr.', 'age': 62, 'title': 'Chief Financial Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Christoph  Bausch M.B.A., Ph.D.', 'age': 52, 'title': 'Executive VP & COO', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Carlos N. Carillo Ph.D.', 'title': 'Senior Vice President of Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.916
priceToSalesTrailing12Months§13.112402
currency§USD
dateShortInterest§1702598400
forwardEps§-0.19
exchange§NCM
quoteType§EQUITY
shortName§SAB Biotherapeutics, Inc.
longName§SAB Biotherapeutics, Inc.
firstTradeDateEpochUtc§1612881000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f04de150-90b5-38f0-b8f2-25c797032921
gmtOffSetMilliseconds§-18000000
targetHighPrice§3.0
targetLowPrice§1.0
targetMeanPrice§2.0
targetMedianPrice§2.0
recommendationMean§2.3
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§0.263
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
